COGA Trial Validates Superiority of Truscreen

Tue, 05 Apr 2022

<0.0001) • TruScreen's specificity was significantly higher than that of LBC (98.6% v’s 97.6%) (p<0.0001) • TruScreen's specificity was also higher than that of hrHPV (98.6% v’s 96.7%) (p<0.0001).

TruScreen Group Limited CEO and Managing Director, Dr. William Foley, said that the results of the COGA trial validate TruScreen as an appropriate primary cervical cancer screening tool in regions with high morbidity and mortality to cervical cancer.

TruScreen Group Limited, a NZX/ASX listed company, has developed a patented, first-in-class, real-time, non-invasive screening technology for the early detection of cervical cancer.

The technology is based on an innovative, proprietary algorithm that detects pre-cancerous cells.

The COGA trial results have highlighted the superiority of TruScreen’s cervical cancer screening method.